Cellectar Biosciences, Inc. SEC filings CLRB
Cellectar Biosciences, Inc. has 1,000 filings in SEC EDGAR's recent list, going back to Nov 7, 2011. Its latest annual report, Form 10-K, was filed on Mar 4, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 13, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Jun 1, 2026 | — |
| CORRESP | Letter to the SEC | May 29, 2026 | — |
| UPLOAD | Letter from the SEC | May 22, 2026 | — |
| EFFECT | Filing | Jul 1, 2025 | — |
| CORRESP | Letter to the SEC | Jun 30, 2025 | — |
| CORRESP | Letter to the SEC | Jun 30, 2025 | — |
| UPLOAD | Letter from the SEC | May 29, 2025 | — |
| DRS | Filing | May 23, 2025 | — |
| EFFECT | Filing | Feb 6, 2025 | — |
| CORRESP | Letter to the SEC | Feb 4, 2025 | — |
| UPLOAD | Letter from the SEC | Feb 3, 2025 | — |
| NT 10-Q | Filing | Nov 13, 2024 | Sep 30, 2024 |
| NT 10-Q | Filing | Aug 14, 2024 | Jun 30, 2024 |
| EFFECT | Filing | Jul 23, 2024 | — |
| CORRESP | Letter to the SEC | Jul 22, 2024 | — |
| UPLOAD | Letter from the SEC | May 31, 2024 | — |
| DEFR14A | Filing | May 16, 2024 | — |
| EFFECT | Filing | Oct 30, 2023 | — |
| CORRESP | Letter to the SEC | Oct 26, 2023 | — |
| UPLOAD | Letter from the SEC | Oct 12, 2023 | — |
| D | Filing | Sep 22, 2023 | — |
| EFFECT | Filing | Dec 2, 2022 | — |
| CORRESP | Letter to the SEC | Nov 30, 2022 | — |
| UPLOAD | Letter from the SEC | Nov 29, 2022 | — |
| DEFR14A | Filing | Jun 7, 2022 | — |
| 25-NSE | Delisting notice | Apr 16, 2021 | — |
| EFFECT | Filing | Feb 1, 2021 | — |
| CORRESP | Letter to the SEC | Jan 28, 2021 | — |
| UPLOAD | Letter from the SEC | Jan 28, 2021 | — |
| D | Filing | Jan 8, 2021 | — |
| EFFECT | Filing | Aug 20, 2020 | — |
| CORRESP | Letter to the SEC | Aug 18, 2020 | — |
| UPLOAD | Letter from the SEC | Aug 18, 2020 | — |
| EFFECT | Filing | Jun 2, 2020 | — |
| CORRESP | Letter to the SEC | Jun 1, 2020 | — |
| UPLOAD | Letter from the SEC | May 15, 2020 | — |
| 25-NSE | Delisting notice | Aug 20, 2019 | — |
| EFFECT | Filing | Jun 11, 2019 | — |
| CORRESP | Letter to the SEC | Jun 11, 2019 | — |
| UPLOAD | Letter from the SEC | Jun 7, 2019 | — |
| D | Filing | May 31, 2019 | — |
| EFFECT | Filing | Jul 26, 2018 | — |
| CORRESP | Letter to the SEC | Jul 25, 2018 | — |
| CORRESP | Letter to the SEC | Jul 25, 2018 | — |
| UPLOAD | Letter from the SEC | Jun 20, 2018 | — |
| EFFECT | Filing | Nov 22, 2017 | — |
| CORRESP | Letter to the SEC | Nov 17, 2017 | — |
| UPLOAD | Letter from the SEC | Nov 16, 2017 | — |
| D | Filing | Oct 13, 2017 | — |
| EFFECT | Filing | Sep 20, 2017 | — |
| CORRESP | Letter to the SEC | Sep 18, 2017 | — |
| CORRESP | Letter to the SEC | Sep 15, 2017 | — |
| UPLOAD | Letter from the SEC | Aug 3, 2017 | — |
| PRER14A | Filing | Aug 2, 2017 | — |
| CORRESP | Letter to the SEC | Aug 2, 2017 | — |
| UPLOAD | Letter from the SEC | Jul 31, 2017 | — |
| UPLOAD | Letter from the SEC | Jun 14, 2017 | — |
| EFFECT | Filing | Nov 22, 2016 | — |
| EFFECT | Filing | Nov 22, 2016 | — |
| CORRESP | Letter to the SEC | Nov 18, 2016 | — |
| CORRESP | Letter to the SEC | Nov 18, 2016 | — |
| CORRESP | Letter to the SEC | Nov 14, 2016 | — |
| UPLOAD | Letter from the SEC | Nov 8, 2016 | — |
| RW | Filing | Oct 21, 2016 | — |
| EFFECT | Filing | Jul 27, 2016 | — |
| CORRESP | Letter to the SEC | Jun 30, 2016 | — |
| UPLOAD | Letter from the SEC | May 31, 2016 | — |
| CORRESP | Letter to the SEC | May 26, 2016 | — |
| PRER14A | Filing | May 26, 2016 | — |
| UPLOAD | Letter from the SEC | May 23, 2016 | — |
| CERTNAS | Auto-generated paper document | Apr 18, 2016 | — |
| 8-A12B | Filing | Apr 18, 2016 | — |
| EFFECT | Filing | Apr 14, 2016 | — |
| CORRESP | Letter to the SEC | Apr 14, 2016 | — |
| CORRESP | Letter to the SEC | Mar 21, 2016 | — |
| UPLOAD | Letter from the SEC | Jan 12, 2016 | — |
| EFFECT | Filing | Dec 18, 2015 | — |
| CORRESP | Letter to the SEC | Dec 18, 2015 | — |
| CORRESP | Letter to the SEC | Dec 16, 2015 | — |
| UPLOAD | Letter from the SEC | Dec 7, 2015 | — |
| CORRESP | Letter to the SEC | Nov 24, 2015 | — |
| EFFECT | Filing | Sep 3, 2015 | — |
| CORRESP | Letter to the SEC | Sep 1, 2015 | — |
| NT 10-Q | Filing | May 18, 2015 | Mar 31, 2015 |
| UPLOAD | Letter from the SEC | Jan 15, 2015 | — |
| D | Filing | Aug 15, 2014 | — |
| CERTNAS | Auto-generated paper document | Aug 14, 2014 | — |
| EFFECT | Filing | Aug 14, 2014 | — |
| 8-A12B | Form 8-a | Aug 14, 2014 | — |
| CORRESP | Letter to the SEC | Aug 14, 2014 | — |
| CORRESP | Letter to the SEC | Aug 13, 2014 | — |
| CORRESP | Letter to the SEC | Aug 12, 2014 | — |
| CORRESP | Letter to the SEC | Aug 11, 2014 | — |
| CORRESP | Letter to the SEC | Jun 25, 2014 | — |
| UPLOAD | Letter from the SEC | Jun 3, 2014 | — |
| CORRESP | Letter to the SEC | May 19, 2014 | — |
| EFFECT | Filing | May 9, 2013 | — |
| EFFECT | Filing | May 9, 2013 | — |
| EFFECT | Filing | Feb 4, 2013 | — |
| EFFECT | Filing | Jul 26, 2012 | — |
| EFFECT | Filing | Jun 7, 2012 | — |
| CORRESP | Letter to the SEC | Jun 7, 2012 | — |
| UPLOAD | Letter from the SEC | Apr 20, 2012 | — |
| EFFECT | Filing | Nov 30, 2011 | — |
| CORRESP | Letter to the SEC | Nov 30, 2011 | — |
| CORRESP | Letter to the SEC | Nov 30, 2011 | — |
Showing 106 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CLRB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Florham Park, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1279704
- Former names
- NOVELOS THERAPEUTICS, INC. (until Feb 11, 2014); COMMON HORIZONS INC (until Jun 2, 2005)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.